Pharmafile Logo
Pharmafocus logo
Advanced Search

IBS

Showing 8 posts of 8 posts found.

EnteroBiotix begins phase 2 trial of IBS treatment

April 3, 2024
Research and Development EnteroBiotix, Gastrointestinal tract, IBS, irritable bowel syndrome

EnteroBiotix has announced that it has dosed the first patient in its multi-centre, randomised, double-blind, placebo controlled clinical trial, which …

News

Janssen’s ulcerative colitis medicine not recommended by NICE for use in adults

January 21, 2020
Manufacturing and Production IBS, Irrated Bowels, NHS, NICE, bowel, ulcerative colitis

NICE has published draft guidance which does not recommend Stelara (ustekinumab) for treating moderately to severely active ulcerative colitis in …

News

Bausch Health buy bankrupt Synergy Pharmaceuticals for $200m

December 13, 2018
Business Services GI, IBS, basuch, cnstipation, synergy pharma

Bankrupt drug developer Synergy Pharmaceuticals has announced that the company is to be acquired by Canadian speciality pharma firm Bausch …

News

Immune system exhaustion associated with irritable bowel syndrome

June 21, 2017
Research and Development IBS, irritable bowel syndrome, t cells

Researchers from the University of Adelaide have linked a specific type of irritable bowel syndrome with the exhaustion of the …

News
Constella

Allergan acquires rights to pioneering IBS treatment from Almirall

October 29, 2015
Medical Communications, Sales and Marketing Allergan, Constella, IBS, linaclotide

Allergan and its commercialisation partner Ironwood Pharmaceuticals have announced that Allergan has acquired the rights to Constella.The companies have acquired …

News
valeant_pharma

Actavis and Valeant see FDA approval for IBS drugs

May 28, 2015
Sales and Marketing Actavis, FDA, IBS, Valeant, brett wells

Both Actavis and Valeant have been shown the green light for their respective irritable bowel syndrome (IBS) treatments from the …

News
Astrazeneca image

AstraZeneca and Ironwood announce $150 million China pact

October 25, 2012
Research and Development, Sales and Marketing AstraZeneca, China, IBS, Ironwood

AstraZeneca has signed a deal with Ironwood to co-develop and co-market Ironwood’s irritable bowel syndrome treatment in China. In August …

News

Positive results for irritable bowel syndrome drug

September 14, 2010
Research and Development Almirall, IBS, linaclotide

A new treatment for patients with irritable bowel syndrome with constipation has produced promising results in a phase III trial. …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025